T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

GOT2 as a metabolic and immunologic target in pancreatic cancer

A new wave of scientific interest is spotlighting GOT2—glutamic-oxaloacetic transaminase 2—as a compelling therapeutic target in the fight against pancreatic cancer, one of the most lethal and treatment-resistant malignancies.

20 Apr 2025

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

17 Apr 2025

Understanding the complex spectrum of Castleman disease

Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features.

11 Apr 2025

Immune system selects the best T cells for targeted defense

The research groups led by Wolfgang Kastenmüller and Georg Gasteiger employed innovative microscopy techniques to observe how specific immune cells, known as T-cells, are activated and proliferate during a viral infection.

10 Apr 2025

Refining the diagnosis of large granular lymphocytic leukemias and their mimics

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL) are the most prominent.

10 Apr 2025

QRICH1 protein discovery opens new avenues for cancer and autoimmune therapies

In a study of the immune systems of mice, scientists at Johns Hopkins Medicine say they have found a new role for a protein, QRICH1, which could become a target for drugs to dial up or down the activation of T cells to fight cancers and autoimmune diseases.

9 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Bach2 protein identified as key regulator in atopic dermatitis

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to social stress.

3 Apr 2025

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.

2 Apr 2025

Nanotechnology innovation aims to improve breast cancer treatment

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

24 Mar 2025

Targeted inhibition of a 'signal jammer' protein may improve tumor response to immunotherapy

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent anion channel 2 (VDAC2) like a signal jammer to prevent the body's anticancer systems from communicating with the immune system.

19 Mar 2025

In the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic Immunotherapy

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

From Hanson Wade Group - 7th Allogeneic Cell Therapies Summit 18 Mar 2025

New research reveals potential path forward for glioblastoma treatment

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy.

17 Mar 2025

Semi-synthetic bile acid could be a promising therapeutic option for TH17-mediated intestinal diseases

A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.

14 Mar 2025

Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center.

14 Mar 2025

Study highlights the role of ELF4 as a key transcription factor in development, immunity, and oncology

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review underscores its molecular complexity and clinical significance, shedding light on its dual role in tumor suppression and oncogenesis.

11 Mar 2025

New test could predict life-threatening side effects of cancer immunotherapy

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs.

10 Mar 2025

New stem cell-based vascular grafts could revolutionize cardiac surgery

Scientists at the Wisconsin National Primate Research Center (WNPRC) and the Morgridge Institute for Research at the University of Wisconsin–Madison have been at the forefront of stem cell research and regenerative biology since James Thomson isolated the first human embryonic stem cell in 1998.

10 Mar 2025

Advancements in molecular diagnostics for hematopoietic and lymphocytic neoplasms

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

27 Feb 2025

LabGenius Therapeutics appoints three experts to its team of scientific advisors

Pioneering therapeutic antibody optimization, LabGenius Therapeutics utilizes advanced technologies to improve drug development and clinical translation.

From LabGenius 27 Feb 2025